Search research articles
Contact Us
Filters
Showing results (121-130 of 132) with videos related to
Page
of 14
Sort By:
The Lancet. Oncology
|
December 7, 2018
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L Locke, Armin Ghobadi, Caron A Jacobson, et al.
Bone Marrow Transplantation
|
March 2, 2025
Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study
Mohamed A Kharfan-Dabaja, Razan Mohty, Neela Easwar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
June 15, 2019
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019
Andrew D Zelenetz, Leo I Gordon, Jeremy S Abramson, et al.
Blood Advances
|
September 21, 2021
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies
Matthew S Davids, Owen A O'Connor, Wojciech Jurczak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 6, 2017
Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission
Daniel J Landsburg, Marissa K Falkiewicz, Joseph Maly, et al.
Nature Medicine
|
December 18, 2021
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
Nathan Hale Fowler, Michael Dickinson, Martin Dreyling, et al.
The New England Journal of Medicine
|
December 12, 2017
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva S Neelapu, Frederick L Locke, Nancy L Bartlett, et al.
Blood
|
January 9, 2024
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update
Martin Dreyling, Nathan Hale Fowler, Michael Dickinson, et al.
Cancer
|
October 1, 2019
Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure
Emily C Ayers, Shaoying Li, L Jeffrey Medeiros, et al.
Blood
|
August 28, 2014
Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis
Adam M Petrich, Mitul Gandhi, Borko Jovanovic, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 132) with videos related to
Sort By:
Page
of 14
The Lancet. Oncology
|
December 7, 2018
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L Locke, Armin Ghobadi, Caron A Jacobson, et al.
Bone Marrow Transplantation
|
March 2, 2025
Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study
Mohamed A Kharfan-Dabaja, Razan Mohty, Neela Easwar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
June 15, 2019
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019
Andrew D Zelenetz, Leo I Gordon, Jeremy S Abramson, et al.
Blood Advances
|
September 21, 2021
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies
Matthew S Davids, Owen A O'Connor, Wojciech Jurczak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 6, 2017
Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission
Daniel J Landsburg, Marissa K Falkiewicz, Joseph Maly, et al.
Nature Medicine
|
December 18, 2021
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
Nathan Hale Fowler, Michael Dickinson, Martin Dreyling, et al.
The New England Journal of Medicine
|
December 12, 2017
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva S Neelapu, Frederick L Locke, Nancy L Bartlett, et al.
Blood
|
January 9, 2024
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update
Martin Dreyling, Nathan Hale Fowler, Michael Dickinson, et al.
Cancer
|
October 1, 2019
Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure
Emily C Ayers, Shaoying Li, L Jeffrey Medeiros, et al.
Blood
|
August 28, 2014
Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis
Adam M Petrich, Mitul Gandhi, Borko Jovanovic, et al.
Page
of 14